Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of March 31, 2018				Fair Value Measurements
	Carrying		Fair		As of March 31, 2018
	Amount		Value		Level 1		Level 2		Level 3
	(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,504	$	1,504	$	-	$	-	$	1,504
Other long-term liabilities:
Warrant liability ⁽²⁾	$	402	$	402	$	-	$	-	$	402
	$	1,906	$	1,906	$	-	$	-	$	1,906

	As of December 31, 2017				Fair Value Measurements
	Carrying		Fair		As of December 31, 2017
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,581	$	1,581	$	-	$	-	$	1,581
Other long-term liabilities:
Warrant liability ⁽²⁾		473		473		-		-		473
	$	2,054	$	2,054	$	-	$	-	$	2,054

⁽¹⁾⁽²⁾See Note 7, Accrued Expenses and Long-Term Liabilities.

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent Consideration Liability and the Underwriters’ Warrant from January 1, 2018 to March 31, 2018 is as follows:

	2018
	January 1,		Payments			Accretion		Cancellation of Obligation/ Conversions		Mark to Market			March 31,
	(unaudited)

Asuragen	$	1,581	$	(77	)	$	-	$	-	$	-		$	1,504

Underwriters Warrant		473		-					-		(71	)		402
	$	2,054	$	(77	)	$	-	$	-	$	(71	)	$	1,906